- Northwest Biotherapeutics (NWBO) enters into agreements with long-time contract manufacturer Cognate Bioservices for the large-scale expansion of the manufacturing, storage, handling and distribution of Northwest's DCVax-L and DCVax-Direct products.
- The company believes that the agreements will give it a head start ahead of Phase III testing of its therapies. Cognate has a "12-year track record of regulatory and operational success with two dozen different cell product trials," Northwest says.
- The firm's DCVax products are personalized immune therapies for solid tumor cancers.
- Shares are +7.4%. (PR)
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs